A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 4,99 (+1.060,47%). A mediana é € 4,99 (+1.060,47%).
| Comprar |
4 |
| Manter |
3 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Cresco Labs strengthens presence in Pennsylvania with purchase of PharmaCann for $50 million
Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » Mais em de.investing.com
Cresco Labs beats Q2 expectations, but stock remains under pressure
Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » Mais em de.investing.com
Cresco Labs: analysts expect smaller quarterly loss on declining revenue on May 8
Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » Mais em finanzen.net
Cresco Labs launches at-the-market stock program for around US$100 million
Cresco Labs has established an at-the-market (ATM) program to permit the sale of subordinate voting shares totaling up to approximately US$100 million. A distribution agreement has been entered with Haywood Securities; no shares have been issued yet. Net proceeds are intended primarily for general corporate purposes and potential acquisitions. Sales will occur on the Canadian Securities Exchange and are not registered for a U.S. public offering. » Mais em de.investing.com
Cresco Labs sells California business as part of strategic realignment
Cresco Labs has announced the sale of its operations in California to strengthen its balance sheet and cash flow, and to focus on higher-margin core markets. CEO Charlie Bachtell cited structural challenges and price pressure in the California market as reasons for the withdrawal. Analysts see uncertain short-term growth prospects, while the company continues to distribute its premium brand FloraCal in the US. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 152,54 mi | 8,55% |
| Ganho bruto | 70,17 mi | 3,77% |
| Ganho líquido | -10,98 mi | 24,42% |
| EBITDA | 9,14 mi | 46,04% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 156,67 mi |
Número de ações | 361,07 mi |
Máximo/mínimo de 52 semanas | € 2,09 - € 0,42 |
| Dividendos | Não |
Beta | 1,72 |
PER (PE Ratio) | -1,67 |
PEG (PEG Ratio) | 0,01 |
P/VC (PB Ratio) | 0,51 |
P/V (PS Ratio) | 0,26 |
Perfil da empresa
A Cresco Labs Inc., juntamente com as suas subsidiárias, cultiva, fabrica e vende produtos de cannabis para venda a retalho e para fins medicinais nos Estados Unidos. Disponibiliza cannabis em flores, canetas de vaporização, resinas vivas, canetas descartáveis e extratos sob a marca Cresco; cartuchos de vaporização, canetas de vaporização, flores, popcorn, shake, pre-rolls, shorties e concentrados sob a marca High Supply; vaporizadores e gomas sob a marca Good News; vaporizadores e comestíveis sob a marca Wonder Wellness Co; e tinturas, cápsulas, bálsamos e óleos sublinguais sob a marca Remedi, bem como produtos de cannabis sob a marca Reserve. A empresa oferece também flores de cannabis sob a marca FloraCal; e confeitos de chocolate e toffee, gomas com sabor a fruta, rebuçados duros e pastilhas elásticas (taffy) sob a marca Mindy's Edibles, bem como licencia a marca Kiva, que produz comestíveis infundidos com cannabis, incluindo confeitos de chocolate, gomas, mentos e tartes. Além disso, a empresa oferece comestíveis infundidos com cannabis sob a marca Sunnyside. Em 27 de janeiro de 2022, detinha e explorava 48 dispensários. A empresa foi constituída em 1990 e tem sede em Chicago, Illinois.
| Nome | Cresco Labs |
| CEO | Charles Bachtell |
| Sede | Chicago,
il EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Produtos farmacêuticos |
| Entrada em bolsa | 03/12/2018 |
| Colaboradores | 2.900 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
Cnq | CL.CN |
Pnk | CRLBF |
Frankfurt | 6CQ.F |
Düsseldorf | 6CQ.DU |
München | 6CQ.MU |